慢性髓性白血病完全细胞遗传学缓解后与伊马替尼相关的骨髓再生障碍
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
作者信息
Khan Khurshid Ahmed, Junaid Ayesha, Siddiqui Nauman Saleem, Mukhtar Khalida, Siddiqui Saleem
机构信息
Department of Oncology, National Oncology Research Institute, Islamabad.
出版信息
J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.
PMID:18460249
Abstract
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
摘要
甲磺酸伊马替尼是一种用于治疗慢性粒细胞白血病的BCR-ABL酪氨酸激酶抑制剂。它是一种安全且耐受性良好的药物，副作用较少且易于控制。我们报告了一例在完全细胞遗传学缓解后发生的与伊马替尼相关的致命性骨髓再生障碍病例。
相似文献
1
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.
2
Hematological and molecular response evaluation of CML patients on imatinib.
J Assoc Physicians India. 2007 Feb;55:109-13.
3
Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Haematologica. 2004 Sep;89(9):ECR32.
4
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011.
5
6
Peripheral neuropathy as an adverse effect of imatinib therapy.
J Clin Pathol. 2011 May;64(5):456. doi: 10.1136/jcp.2010.085936. Epub 2011 Jan 28.
7
Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
J Assoc Physicians India. 2005 Apr;53:291-5.
8
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Cas Lek Cesk. 2006;145(5):377-82.
9
Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
J Assoc Physicians India. 2007 Feb;55:99-100.
10
Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Pathology. 2010 Jan;42(1):84-5. doi: 10.3109/00313020903434686.
引用本文的文献
1
Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon.
Eurasian J Med Oncol. 2019;3(3):182-185. doi: 10.14744/ejmo.2019.94710.
2
Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma.
Case Rep Hematol. 2019 Sep 22;2019:4861673. doi: 10.1155/2019/4861673. eCollection 2019.
3
MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.
Blood Res. 2015 Sep;50(3):154-9. doi: 10.5045/br.2015.50.3.154. Epub 2015 Sep 22.
4
Synchronous presentation of chronic myeloid leukemia with carcinoma penis: a rare presentation.
J Clin Diagn Res. 2014 Sep;8(9):QD01-2. doi: 10.7860/JCDR/2014/8760.4827. Epub 2014 Sep 20.
5
Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients.
Indian J Hematol Blood Transfus. 2010 Jun;26(2):56-61. doi: 10.1007/s12288-010-0030-6. Epub 2010 Oct 5.
Zotero 插件